NANOSENSING

The scientific foundation is the NanoPlasmonic Technology Platform, or NPTP, developed around modified metallic nanoparticles and optical spectroscopy.

The historical technical materials describe the use of plasmonic optical responses to detect and quantify selected biomarkers, including cardiac troponin I.

The proposed diagnostic configuration combines:

This architecture supports both a defined first product and a longer-term platform-development strategy.

The NANOSENSING program is supported by historical scientific and engineering work undertaken by researchers associated with Recife, Brazil.

The source materials describe development of the NPTP technology, prototype instrumentation, patent-related work and historical clinical-testing activity associated with the cardiac troponin application.

These materials provide an identifiable technical foundation for renewed product development and independent assessment.

The next enterprise phase is designed to establish the current technical position through documented review of the underlying research, intellectual property, prototype condition, analytical performance and clinical evidence.

Historical performance figures, testing timelines and regulatory assertions will be independently verified before being used as current product specifications or commercialization claims.

NANOSENSING's commercial proposition combines diagnostic hardware, recurring test consumables and platform intellectual property.

The platform may support additional biomarker applications where the underlying science, intellectual-property rights, clinical requirements and commercial case justify further development.

No current sales, customer contracts, product pricing or recurring revenues should be asserted without verified supporting records.

Of Joseph PB&T's investment strategy is to organize NANOSENSING as an independently governed, internationally investable diagnostics enterprise.

The contemplated structure places a Cayman-incorporated parent company at the center of enterprise governance, international capitalization and long-term public-market readiness.

Appropriate operating and development arrangements may include Brazil, the United States and other relevant jurisdictions.

The enterprise structure will be determined with reference to the existing corporate and intellectual-property position.

The enterprise capitalization will be structured around the verified intellectual-property position, including the rights associated with Nanosensing Technologies, Inc. and the historical participation of Of Joseph PB&T Foundation. The appropriate ownership, licensing and commercialization arrangements will be established through definitive agreements with the relevant rights holders.

Of Joseph PB&T's originating and structuring role must remain distinct from the ownership, obligations and governance of the eventual operating enterprise.

NANOSENSING sits within the investment activities associated with Peixe Rosa, Of Joseph PB&T's life-sciences and translational-medicine ecosystem.

This relationship provides a framework for connecting scientific development with relevant research institutions, clinical expertise, translational capabilities and enterprise execution in Brazil.

Recife and the wider Pernambuco research environment offer a practical setting for technical assessment, qualified talent recruitment and institutional collaboration.

Specific laboratory, hospital and research activities will proceed under the relevant agreements, authorizations and technical protocols.

The objective is to combine the advantages of the Brazilian scientific environment with international standards of product development, governance and commercialization.

Of Joseph PB&T is presenting an initial co-investment opportunity of US$6 million to support the establishment and advancement of NANOSENSING as an independent international diagnostics enterprise.

The capitalization is intended to support the following development priorities:

• Corporate organization, governance and intellectual-property arrangements.
• Independent assessment of the underlying technology and existing evidence.
• Diagnostic instrument and consumables engineering.
• Analytical and clinical validation planning and execution.
• Regulatory strategy and quality-management development.
• Manufacturing feasibility and supply-chain preparation.
• Recruitment of experienced enterprise and technical leadership.
• Commercial partner engagement and international market preparation.

The deployment sequence will follow approved operating budgets and measurable development milestones.

This capitalization represents the initial enterprise financing target, not a representation that all regulatory authorizations, manufacturing operations or global commercial launches can be completed within that amount.

Any eventual public listing remains dependent on applicable requirements, enterprise development and market conditions.

NANOSENSING combines a recognizable clinical application with a technology architecture capable of supporting multiple commercial pathways.

Its investment proposition rests on five foundations:

The commercial opportunity is to convert prior scientific development into a disciplined, internationally structured diagnostics business.

Of Joseph PB&T welcomes inquiries from qualified co-investors, strategic industry participants and commercial partners interested in the capitalization and development of NANOSENSING.

Detailed participation terms are provided privately to qualified investors.